GlassScriptPhysician profile
Te-Shao Hsu
NPI 1255300042
$73,444.07
in general payments reported to CMS, 2019-2025
37 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $11K · 2021: $11K · 2022: $3,303 · 2023: $1,304 · 2024: $7,877 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,463 · Food and Beverage: $5,200 · Travel and Lodging: $655 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,462.50 |
| Food and Beverage | $5,200.40 |
| Travel and Lodging | $655.43 |
| Education | $204.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $24,126.80 | 2019 | |
| Amgen INC. | $23,342.81 | 2020-2025 | Otezla, Otezla |
| Dermira, INC. | $10,617.08 | 2019 | |
| Abbvie INC. | $8,075.54 | 2020-2025 | |
| Merz North America, INC. | $1,236.71 | 2019-2025 | Xeomin |
| Ucb, INC. | $596.82 | 2022-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $553.32 | 2019-2025 | Ilumya |
| Lilly USA, LLC | $480.25 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $419.99 | 2023-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $419.80 | 2019-2025 | |
| Genzyme Corporation | $390.02 | 2020-2025 | |
| Incyte Corporation | $332.18 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $284.24 | 2019-2024 | Aklief, Oracea, Epsolay |
| Dermavant Sciences, INC. | $237.66 | 2022-2024 | Vtama |
| Revance Therapeutics, INC. | $225.16 | 2024-2025 | Daxxify |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Te-Shao Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.